Aptimmune

About:

Aptimmune is a biotechnology company that specializes on developing mucosal vaccines for swine.

Twitter/X: aptimmune

Top Investors: Kemin Industries, The Yield Lab, Cultivation Capital, Missouri Technology Corporation, Arsenal Capital Partners

Description:

Aptimmune is a biotechnology company that focuses on developing a muscoal vaccine against viral diseases swine. It focuses on swine vaccines and the prevention of two major diseases, Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and influenza. It utilizes novel technologies to create effective nasal delivery vaccines against PRRSV such as the proprietary pig alveolar macrophage cell line ZMAC. The company was founded in 2010 and headquartered in St. Louis, Missouri.

Total Funding Amount:

$8.85M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

St Louis, Missouri, United States

Founded Date:

2010-01-01

Contact Email:

faza(AT)aptimmune.com

Founders:

Federico Zuckermann, Heather Bessoff

Number of Employees:

1-10

Last Funding Date:

2022-01-10

IPO Status:

Private

Industries: